Rachna T. Shroff, MD, MS, FASCO, is a professor with tenure in the Department of Medicine, chief of the Division of Hematology and Oncology, medical director for the Oncology Service Line, and associate dean for Clinical and Translational Research for the University of Arizona College of Medicine – Tucson. She also serves as associate director of Clinical Investigations and co-leader of the Gastrointestinal Clinical Research Team at the University of Arizona Cancer Center (UACC). She came to UACC from MD Anderson Cancer Center in Houston, where she was on faculty from 2010-18, after completing her medical oncology fellowship there.
Dr. Shroff is a clinical and translational investigator focused on developing novel therapies for pancreatic and hepatobiliary cancers. She holds multiple positions nationally due to her expertise in these areas, including serving as the Hepatobiliary Subcommittee co-chair for the Southwest Oncology Group (SWOG) and as chair for GI ASCO 2024, a meeting sponsored by the American Society of Clinical Oncology focused on gastrointestinal cancers. Most recently, she was elected to serve on the ASCO Nominating Committee. She also is a member of the Scientific and Medical Advisory Board for the Cholangiocarcinoma Foundation.
Dr. Shroff has led numerous clinical trials focusing on pancreaticobiliary tumors and is the national principal investigator (PI) for SWOG 1815, which investigated a triplet chemotherapy regimen as a potential new standard of care for biliary cancers. This is based on a phase 2 study she led that is now published in JAMA Oncology. Dr. Shroff has been invited to speak at national and international meetings on topics related to targeted therapies for pancreatic and biliary cancers, and has numerous peer-reviewed publications in this area.